Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sales Force Effectiveness Japan
June 5, 2006
- Vesicare Drug of Choice for OAB: Prof. Yamaguchi
June 5, 2006
- INTERPHEX JAPAN
June 5, 2006
- Early Discovery, Continuous Treatment with Anticoagulants Important for Cerebral Infarction
June 5, 2006
- BUSINESS NEWS IN BRIEF
June 5, 2006
- More than 90% of Consumers Aware of GE Drugs: Sawai
June 5, 2006
- Top 25 JPMA Member Companies Report Combined Growth in Sales, Profits
June 5, 2006
- Generics Account for 30% of Prescriptions in Dermatology
June 5, 2006
- Otsuka: Major Products Drive Steady Growth in Sales
June 5, 2006
- Higher Interest but No Marked Increase in Use of Generics: Survey
June 5, 2006
- Hisamitsu Announces Midterm Management Plan for FY2007-2009
June 5, 2006
- Dr Aoki Discusses Plans for 2nd Term as President of JPMA
June 5, 2006
- 4 Major Wholesalers Post Good Sales, Profits in FY2005
June 5, 2006
- Astellas to Focus on Pipeline Aiming at Global Top 10: Mr Nogimori
June 5, 2006
- Mediceo Paltac HD: Sales Approach \2 Trillion
June 5, 2006
- Chuikyo Approves 8 Drugs for Inclusion in NHI Price List
June 5, 2006
- Suzuken: Addition of Astis Boosts Sales
June 5, 2006
- Chuikyo Approves NHI Price Listing of Nicotine Patch
June 5, 2006
- Alfresa HD: Sales Exceed \1.4 Trillion
June 5, 2006
- New Dosage Forms of Itraconazole, Moxifloxacin Recommended for Approval
June 5, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…